bioCSL Influenza Vaccine PASS 2015

  • Research type

    Research Study

  • Full title

    Observational influenza vaccine active surveillance study: A Phase IV Prospective Multi-Centre Cohort Study to Evaluate the Reactogenicity of bioCSL’s influenza virus vaccine (2015/2016 formulation; CSLCT-SAF-15-17)

  • IRAS ID

    187081

  • Contact name

    James Larcombe

  • Contact email

    james.larcombe@nhs.net

  • Sponsor organisation

    bioCSL PTY LTD

  • Clinicaltrials.gov Identifier

    PL22236/0001 (MHRA Licence Number), Product reference

  • Duration of Study in the UK

    0 years, 4 months, 31 days

  • Research summary

    This observational research study will be implemented through the primary care section of division 5 of the National Institute for Health Research in the United Kingdom.
    People who have, or are just about to be, routinely vaccinated with bioCSL’s influenza virus vaccine will be invited to enrol in the study. Study participants will be asked to report solicited adverse events occurring within seven days after each vaccination and medically attended adverse events that have symptom onset within seven days after each vaccination, via an internet based survey. The rates of adverse events after vaccination in the overall cohort, and in pre-specified age subgroups of the cohort will be described.
    This proposed multicentre, observational study, will include approximately 400 patients being treated with bioCSL’s influenza virus vaccine at approximately 10 sites throughout United Kingdom.
    This observational post-marketing study is designed to capture the population receiving bioCSL’s influenza virus vaccine regardless of age or health status in order to provide a picture of the safety profile in routine practice. Pregnant and immunocompromised participants, and children aged less than 5 are not excluded from this study if they have been administered bioCSL’s influenza virus vaccine as part of routine care, or inadvertently prior to enrolment in the study.

  • REC name

    North West - Preston Research Ethics Committee

  • REC reference

    15/NW/0632

  • Date of REC Opinion

    23 Jul 2015

  • REC opinion

    Favourable Opinion